Bae S-C, Lee Y H
Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea (Republic of).
Department of Rheumatology, Korea University College of Medicine, Seoul, Korea (Republic of).
Z Rheumatol. 2020 Apr;79(3):312-318. doi: 10.1007/s00393-019-00689-y.
This study systemically reviewed the evidence regarding the association between plasminogen activator inhibitor‑1 (PAI‑1) 4G/5G polymorphism and susceptibility to systemic lupus erythematous (SLE)/lupus nephritis (LN) and rheumatoid arthritis (RA) and the relationship between circulating PAI‑1 levels and SLE/LN and RA.
We conducted a meta-analysis on the association between the PAI‑1 4G/5G polymorphism and SLE/LN or RA risk and serum/plasma PAI‑1 levels in patients with SLE/LN and RA and healthy controls.
Nine articles including 657 patients with SLE and 668 controls and 567 patients with RA and 772 controls were included. No association was revealed between SLE and PAI‑1 4G allele in all study subjects (odds ratio [OR] = 0.944, 95% confidence interval [CI] = 0.808-1.102, p = 0.463). Ethnicity-based stratification showed no association between the PAI‑1 4G allele and SLE among Europeans and Asians. No association was detected between LN and RA and the PAI‑1 4G allele (OR = 0.886, 95% CI = 0.713-1.102, p = 0.278; OR = 0.8736, 95% CI = 0.747-1.020, p = 0.088, respectively) or between SLE/LN and RA and the PAI‑1 4G/5G polymorphism using the recessive and dominant models and homozygote contrast. The circulating PAI‑1 level was significantly higher in the SLE group than in the control group (standardized mean difference [SMD] = 0.337, 95% CI = 0.057-0.619, p = 0.019). However, serum/plasma PAI‑1 level showed no significant difference between RA and control group (SMD = 0.333, 95% CI = -0.6989-1.35, p = 0.527).
There was no association between the PAI‑1 4G/5G polymorphism and SLE/LN and RA development and significantly higher levels of circulating PAI‑1 were observed in patients with SLE but not in those with RA.
本研究系统评价了纤溶酶原激活物抑制剂-1（PAI-1）4G/5G多态性与系统性红斑狼疮（SLE）/狼疮性肾炎（LN）及类风湿关节炎（RA）易感性之间的证据，以及循环PAI-1水平与SLE/LN和RA之间的关系。
我们对PAI-1 4G/5G多态性与SLE/LN或RA风险以及SLE/LN和RA患者及健康对照者血清/血浆PAI-1水平之间的关联进行了荟萃分析。
纳入9篇文章，包括657例SLE患者和668例对照，以及567例RA患者和772例对照。在所有研究对象中，SLE与PAI-1 4G等位基因之间未发现关联（优势比[OR]=0.944，95%置信区间[CI]=0.808-1.102，p=0.463）。基于种族的分层显示，欧洲人和亚洲人中PAI-1 4G等位基因与SLE之间无关联。未检测到LN和RA与PAI-1 4G等位基因之间的关联（OR=0.886，95%CI=0.713-1.102，p=0.278；OR=0.8736，95%CI=0.747-1.020，p=0.088），也未发现SLE/LN和RA与PAI-1 4G/5G多态性之间使用隐性和显性模型及纯合子对比的关联。SLE组循环PAI-1水平显著高于对照组（标准化均值差[SMD]=0.337，95%CI=0.057-0.619，p=0.019）。然而，RA组与对照组血清/血浆PAI-1水平无显著差异（SMD=0.333，95%CI=-0.6989-1.35，p=0.527）。
PAI-1 4G/5G多态性与SLE/LN和RA的发生无关联，SLE患者循环PAI-1水平显著升高，而RA患者则未升高。
